|Bid||1.2800 x 1800|
|Ask||1.3400 x 1300|
|Day's range||1.2500 - 1.3900|
|52-week range||1.0800 - 8.1000|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
STONY BROOK, N.Y., May 12, 2022--Revenues at Record $6.2 Million, up 130% Year-over-Year; Cash at $6.5 Million Inclusive of Net Proceeds from Offering and Strong Cash Collections.
STONY BROOK, N.Y., May 09, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events’ sub-page of the Comp
STONY BROOK, N.Y., April 06, 2022--Applied DNA Clinical Labs secures NYC-based 'Return-to-Office' health services contract for COVID-19 testing.